miR‐181a overexpression predicts the poor treatment response and early‐progression of serous ovarian cancer patients

Ovarian cancer (OC) remains a leading cause of gynecological cancer‐related death worldwide, characterized by poor 5‐year survival. Molecular markers could serve as crucial tools of personalized prognosis and therapy. Herein, we present miR‐181a as novel predictor of OC prognosis, using five indepen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:International Journal of Cancer Ročník 147; číslo 12; s. 3560 - 3573
Hlavní autoři: Panoutsopoulou, Konstantina, Avgeris, Margaritis, Magkou, Paraskevi, Mavridis, Konstantinos, Dreyer, Tobias, Dorn, Julia, Obermayr, Eva, Reinthaller, Alexander, Michaelidou, Kleita, Mahner, Sven, Vergote, Ignace, Loverix, Liselore, Braicu, Ioana, Sehouli, Jalid, Zeillinger, Robert, Magdolen, Viktor, Scorilas, Andreas
Médium: Journal Article
Jazyk:angličtina
Vydáno: Hoboken, USA Wiley 15.12.2020
John Wiley & Sons, Inc
Wiley Subscription Services, Inc
Témata:
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Biomarkers, Tumor - genetics
Cancer
Cancer therapies
Chemotherapy
Cohort Studies
Cystadenocarcinoma, Serous
Cystadenocarcinoma, Serous - genetics
Cystadenocarcinoma, Serous - therapy
Cytoreduction Surgical Procedures
Disease Progression
epithelial ovarian cancer
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Gynecological cancer
Health Sciences
Humans
Medical prognosis
Medical research
MicroRNAs
MicroRNAs - genetics
microRNA‐181a
Middle Aged
molecular diagnostics
noncoding RNA
Ovarian cancer
Ovarian Neoplasms
Ovarian Neoplasms - genetics
Ovarian Neoplasms - therapy
ovarian tumors
Patients
Platinum
Platinum - therapeutic use
Precision medicine
Prognosis
Surgery
Survival
Survival Analysis
Treatment Outcome
Up-Regulation
Επιστήμες Υγείας
molecular diagnostics
microRNA-181a
noncoding RNA
epithelial ovarian cancer
ovarian tumors
ISSN:0020-7136, 1097-0215, 1097-0215
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Ovarian cancer (OC) remains a leading cause of gynecological cancer‐related death worldwide, characterized by poor 5‐year survival. Molecular markers could serve as crucial tools of personalized prognosis and therapy. Herein, we present miR‐181a as novel predictor of OC prognosis, using five independent OC cohorts. In particular, a screening (n = 81) and an institutionally independent validation (n = 100, OVCAD multicenter study) serous OC (SOC) cohorts were analyzed. Bagnoli et al (2016) OC179 (n = 124) to OC133 (n = 100) and TCGA (n = 489) served as external validation cohorts. Patients’ survival and disease progression were assessed as clinical endpoint events. Bootstrap analysis was performed for internal validation and decision curve analysis was utilized to evaluate clinical benefit. miR‐181a overexpression was unveiled as powerful and independent molecular predictor of patients’ poor survival and higher risk for disease progression after debulking surgery and platinum‐based chemotherapy. Analysis of the OVCAD institutionally independent cohort, as well as of Bagnoli et al. and TCGA external cohorts further confirmed the unfavorable prognostic nature of miR‐181a overexpression in SOC. Strikingly, multivariate prognostic models incorporating miR‐181a with established disease markers clearly improved patients’ risk‐stratification and offered superior clinical benefit in OC prognostication. Conclusively, miR‐181a evaluation could augment prognostic accuracy and support precision medicine decisions in OC. What's new? Ovarian cancer remains difficult to treat and has a low 5‐year survival rate. Biological markers associated with the disease could help develop personalized therapy or refine prognosis. The microRNA miR‐181a has been shown to mediate EMT transition and inhibit apoptosis. Here, the authors looked for miR‐181a in five independent cohorts of ovarian cancer patients. They found that miR‐181a overexpression predicted poor survival and increased risk of disease progression. Testing for this marker could improve the way that patients’ risk is assessed and help guide treatment decisions.
Bibliografie:Funding information
Stavros Niarchos Foundation, Grant/Award Number: 16785; Wilhelm Sander Stiftung, Grant/Award Number: 2016‐024.1; European Commission as a FP6 Specific Targeted Research and Innovation Project, Grant/Award Number: 018698
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0020-7136
1097-0215
1097-0215
DOI:10.1002/ijc.33182